Johnson & Johnson’s lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in preclinical studies. Data shows the investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutralizing antibodies,” successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the preclinical study....